BDX Stock Analysis: Buy, Sell, or Hold?
BDX - Becton, Dickinson and Co.
$203.48
2.39 (1.19%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 04, 2026
3d
Get Alerted When BDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BDX shows positive signals but monitor for confirmation. Market pricing in 0.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BDX shows positive signals but monitor for confirmation. Market pricing in 0.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$263.29
Based on 5.2% avg growth
INTRINSIC VALUE TODAY
$163.48
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BDX is currently trading at $203.48, which is considered fair relative to its 30-day fair value range of $197.07 to $205.68. The stock's valuation (Forward PE: 12.7) is in line with its historical norms (12.9). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This pessimistic expectation contrasts with the company's recent 25.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BDX is in a strong uptrend. The price is approaching resistance at $209.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BDX is in a strong uptrend. The price is approaching resistance at $209.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$197.07 -
$205.68
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($206.67)
Fair Price Analysis
30-Day Fair Range
$197.07 -
$205.68
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$195.63
Resistance Level
$209.12
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
12.66
Wall Street Target
$206.67
(+2.8%)
Revenue Growth (YoY)
8.3%
Earnings Growth (YoY)
25.2%
Profit Margin
7.7%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
12.7 vs 12.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$199.68
(-1%)
2-Year Target
$198.28
(-1%)
3-Year Target
$196.90
(-2%)
3-Yr Target (if PE normalizes)
(PE: 13→13)
$200.59
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 6.3%)
$425.23
(+112%)
Base:
(SPY PE: 12.7, Growth: 6.3%)
$241.46
(+20%)
Bear:
(PE: 10.8, Growth: 6.3%)
$205.24
(+2%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (35x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 34.69 | Current EPS (TTM): $5.82
Bull Case
$444.22
(+118%)
Analyst growth 100.0%, PE expands to 38.2
Base Case
$403.84
(+99%)
Market implied 100.0%, PE stable at 34.7
Bear Case
$137.31
(-33%)
Severe decline -20.0%, PE contracts to 29.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.7 to 12.9
Stabilization Target:
$204.86
(+1.9%)
PE Expansion Potential:
+1.9%
Last updated: January 31, 2026 1:38 AM ET
Data refreshes hourly during market hours. Next update: 2:38 AM
Data refreshes hourly during market hours. Next update: 2:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BDX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2025-09-29
Michael Feld
SELL
58 shares
2025-09-26
Claire Fraser
SELL
917 shares
2025-09-10
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$92 | 63 BUY |
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$608 | 58 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$191 | 58 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$292 | 57 HOLD |
|
ALGN
Align Technology Inc |
BUY
18 analysts |
$184 | 62 BUY |
Advanced BDX Option Strategies
Professional options setups generated by AI based on today's BDX price and gamma walls.
